Statins, Cholesterol and Cognitive Decline in Alzheimer's

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medication Repurposing to Stop Cognitive Decline in Dementia

NCT05817188

Alzheimer Dementia Dementia Disorders

COMPLETED

Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients

NCT00842920

Mild Cognitive Impairment

UNKNOWN PHASE4

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044

Alzheimer Disease

COMPLETED PHASE2

Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders

NCT00004557

Dementia

COMPLETED

Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction

NCT01554475

Dementia Cognitive Impairment

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Dementia Statins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Alzheimer's disease

Prospective cohort study based on data from the Stockholm Creatinine Measurements (SCREAM) project. Patients diagnosed with AD and mixed dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases are included.

STA 4783

Intervention Type DRUG

Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STA 4783

Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients with AD and mixed dementia registered in SveDem and from SCREAM.

Exclusion Criteria

* All patients with a missing MMSE score at diagnosis date will be excluded from the analyses.
* Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No